<DOC>
	<DOCNO>NCT00739414</DOCNO>
	<brief_summary>This study characterize safety , tolerability , biological activity , pharmacokinetics LBH589 Japanese patient advance solid tumor whose disease progress despite standard therapy , standard therapy exists .</brief_summary>
	<brief_title>Dose-escalating Study LBH589 Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm , advance solid tumor whose disease progress despite available standard therapy , standard therapy exists . 2 . At least one measurable nonmeasurable lesion define modified RECIST Criteria solid tumor 3 . Age ≥20 year old 4 . World Health Organization ( WHO ) Performance Status ≤2 5 . Patients must follow laboratory value define protocol 6 . Life expectancy ≥ 12 week 7 . Written inform consent obtain 1 . Patients evidence CNS tumor metastasis 2 . Patients pleural effusion and/or ascites drain 3 . Patients peripheral neuropathy ≥ CTCAE grade 2 4 . Impaired cardiac function define protocol 5 . Acute chronic liver renal disease 6 . Other concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risk compromise compliance protocol 7 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication 8 . Patients receive chemotherapy ≤4 week prior start study drug recover side effect therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Histone Deacetylases</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>LBH589</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Adult</keyword>
</DOC>